<DOC>
	<DOCNO>NCT00298155</DOCNO>
	<brief_summary>Prostate cancer ( CaP ) commonly diagnosed cancer among male U.S. second lead cause cancer-related mortality . More 230,000 men diagnose prostate cancer USA year 30,000 die disease . Androgen deprivation , elimination testosterone active metabolite , remain single effective intervention available treatment advance prostate carcinoma . This usually achieve surgical removal testis ( orchiectomy ) , suppress production testosterone ( LHRH agonist ) and/or block androgen receptor site ( antiandrogens ) . Unfortunately , androgen suppression cure disease . Most patient progress within 0-5 year , patient ultimately progress cancer eliminate initial therapy ( usually prostatectomy radiation ) . Hormone suppression treatment eliminate detectable level testosterone blood . However , testosterone level tissue remain high enough stimulate androgen receptor . Overexpression androgen receptor present cell line demonstrate `` androgen independence , '' i.e. , resistant androgen-suppressive therapy . Approximately 95 % testosterone supply testis , remain 5 % supply adrenal gland . The presumption standard androgen deprivation achieve optimal level androgen suppression patient base level androgen result orchiectomy . However , adrenal androgen level unaffected standard mode androgen deprivation , 5 % body 's testosterone remain despite hormone therapy . The hypothesis study effective suppression androgen axis elimination adrenal androgen effective suppression testosterone metabolites lower intraprostatic androgen level , minimize activation androgen receptor augment natural cell death ( apoptosis ) . The investigator propose test hypothesis administer neoadjuvant ( pre-surgery ) androgen deprivation therapy different type prostatectomy patient clinically localized prostate cancer . The investigator assay serum intraprostatic androgen level , assess relative level apoptosis normal malignant tissue .</brief_summary>
	<brief_title>Maximal Suppression Androgen Axis Clinically Localized Prostate Cancer</brief_title>
	<detailed_description>Androgen deprivation principal mean control advanced prostate cancer , cure disease patient ultimately progress tumor eliminate definitive local therapy . It demonstrate despite androgen deprivation LHRH agonists orchiectomy , prostate tissue prostate cancer maintain level androgens adequate stimulate androgen receptor . These level androgen may continue stimulate receptor allow survival tumor cell induction resistance overexpression receptor . The presumption standard androgen deprivation achieve optimal level androgen suppression patient base level androgen achieve castration , achieve relatively short term control cancer majority patient . The hypothesis study effective suppression androgen axis elimination adrenal androgen effective suppression conversion dihydrotestosterone lower intraprostatic androgen level , minimize activation androgen receptor augment apoptosis . We propose test hypothesis prospective , randomize trial , administer neoadjuvant androgen deprivation therapy different type prior radical prostatectomy patient clinically localized prostate cancer 3 month . Plan therapy Patients clinically localize ( cT1-T2 ) prostate cancer , intermediate-high risk relapse candidate radical prostatectomy treat one three regimen : - Goserelin dutasteride - Goserelin bicalutamide dutasteride - Goserelin bicalutamide dutasteride ketoconazole Patients undergo radical prostatectomy 3 month initiation treatment . Preoperative intraoperative biopsy prostate gland utilized analysis prostatic hormone , gene expression apoptosis .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Men 18 year old histologic diagnosis clinically localized prostate cancer prior radical prostatectomy define : Clinical stage T1T2b PSA le 20 Gleason score 710 2 . Patient 's tumor must consider surgically resectable . 3 . ECOG performance status 01 . 4 . Life expectancy great 2 year . 5 . Able understand give inform consent . 6 . Laboratory value must within specify limit . 1 . Patients locally advanced high risk disease meeting criterion define . 2 . Patients total testosterone le 280 ng/dL . 3 . Patients receive investigational therapy . 4 . Patients active serious infection serious underlie medical condition . 5 . Dementia significantly alter mental status would prohibit understanding and/or give informed consent . 6 . Histologic evidence small cell carcinoma prostate . 7 . Patients currently receive active therapy neoplastic disorder . 8 . Patients receive androgen , estrogens progestational agent . 9 . Patients take drug herbal supplement affect androgen metabolism ( e.g. , spironolactone , aprepitant , bexarotene , clarithromycin , itraconazole , ketoconazole , St. John 's wort ) . 10 . Patients chronic active hepatitis . 11 . Patients take following medication discontinue medication three month administration ketoconazole ; statin cholesterol medication , cyclosporine , isoniazid , rifampin , terfenadine , triazolam astemizole . 12 . Patients history cerebrovascular accident , deep venous thrombosis , pulmonary embolus , unstable angina clinical congestive heart failure . 13 . Medical condition , , opinion investigator would jeopardize either patient integrity data obtain . 14 . Patients unwilling use contraceptive study . 15 . Patients risk nodal involvement great 10 % define Partin table receive bone scan CT pelvis prior screen study part standard care .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>